A: Overweight or obese individuals, with or without type 2 diabetes, may benefit from Semaglutide or Tirzepatide
At week 48, the relative decrease in liver fat was 81.7% among those taking 8mg doses of retatrutide, and 86% for those taking 12mg
Treatment plans are individualized we do not use one-size-fits-all protocols
The primary risks include gastrointestinal side effects (nausea, vomiting, diarrhoea), undesirable weight loss in patients at risk of malnutrition, delayed gastric emptying that may impair levodopa absorption, and rare but serious complications such as pancreatitis and dehydration leading to acute kidney injury
Semaglutide injections work best when taken consistently each week, and research shows that timing matters for both medication effectiveness and tolerability